[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-functioning\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-functioning":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,55,89,121,153,178],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100625207","this-study-investigates--hydroxy--methylbutyrate-hmb-and-2-hydroxybenzylamine-2-hoba-when-administered-either-individually-or-in-combination-contributes-to-an-increased-quality-of-health-specifically-improving-muscular-strength-and-cognitive-functioning-in-adults-over-the-age-of-65-100625207",false,"NCT07419633","This Study Investigates β-hydroxy-β-methylbutyrate (HMB) and 2-hydroxybenzylamine (2-HOBA), When Administered Either Individually or in Combination Contributes to an Increased Quality of Health, Specifically Improving Muscular Strength and Cognitive Functioning in Adults Over the Age of 65.","The Effects of Beta-Hydroxy-Beta-methylbutyrate (HMB) and\u002For 2-hydroxybenzylamine (2-HOBA) on Markers of Health Span in Older Adults. A Randomized Control Trial.","H2AGE","Inclusion Criteria:\n\n•. 65 years of age\n\n* English or French speaking\n* Females not of childbearing potential\n* Willing to maintain current lifestyle and dietary habits, including level of physical activity, allowed medication\u002Fsupplements habits for the duration of the study\n\nExclusion Criteria:\n\n* Known cardiac diseases, known arterial fibrillation, hepatic diseases, immune diseases (e.g. Individuals with an acute infectious disease, autoimmune disease or are immune compromised), ulcers, asthma, gout, severe anemia, hay fever, nasal polyps.\n\n  * Chronic kidney disease \\[estimated glomerular filtration rate (GFR) \\\u003C 35 mL\u002Fmin\\].\n  * Neurological injury\u002Fdisorder with significant persistent neurological or functional deficit (e.g., stroke with hemiparesis, spinal cord injury, muscular dystrophy, myopathy, myasthenia gravis, Parkinson's disease, peripheral polyneuropathy).\n  * Neuropsychological condition and\u002For cognitive impairment that, in the QI's opinion, could interfere with study participation\n  * History of confirmed chronic obstructive pulmonary disease with a severity grade \\> 2 on the Medical Research Council Dyspnea Scale.\n  * Uncontrolled hypothyroidism or hyperthyroidism. Hypothyroid patients who have changed their dose of hormone replacement therapy in the 6 weeks before screening are not eligible.\n  * Underlying muscle diseases, including a history of or currently active myopathy (e.g., dermatomyositis, polymyositis, etc.) or muscular dystrophies.\n  * Confirmed rheumatoid arthritis, acquired immunodeficiency syndrome (AIDS), type 1 or type 2 diabetes mellitus.\n  * History of cancer in the last 6 months.\n  * Not on any medications including NHPs\u002Fliving with medical conditions that would compromise the study outcome or the safety of the research participant.\n  * Known allergy to study medication or its components (non-medicinal ingredients).\n  * Allergy to aspirin\u002Fsalicylate or if using other drugs containing acetylsalicylic acid or other salicylates and a history of ASA-sensitive asthma\u002Fbronchospasm\n\nThe following list of medications\u002FNHPs will be excluded (and weaned as seen necessary by the study physician) prior to and during the study:\n\n* Participants on newly initiated cholesterol-lowering medication will be excluded. Those on stable regimens for ≥3 months will be included and will be monitored for potential interactions as per the HMB monograph.\n* Medications associated with muscle weakness or immune effects (i.e., oral glucocorticoids).\n* Medications or supplements affecting skeletal muscle metabolism or weight including: Use of MAO-I's (monoamine oxidase inhibitors), additional consumption of 2-HOBA, Vitamin D or HMB, anabolic steroids, selective androgen receptor modulators (SARMs), corticosteroids, GLP-1s, or other weight loss medications).\n* Excessive protein supplementation (i.e., \\>2.0 g\u002Fkg\u002Fday).\n* All participants must be on a stable dose of allowed supplements\u002Fmedications for at least 3 months prior to enrollment. All concomitant therapies will be documented.\n\nNon-pharmacological interventions that could influence study outcomes (e.g., pulmonary rehabilitation, structured exercise programs) will not be permitted.\n\nParticipants undergoing such therapies will be excluded. Any new interventions started during the study must be reported and if judged inappropriate, will result in withdrawal from the trial.",true,"ALL","65 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this study, participants will be assigned to receive HMB, 2-HOBA, a combination of both, or a comparison supplement for a set period of time. During the study, participants will attend scheduled visits where researchers will assess muscle strength, physical function, and overall health. Blood samples may be collected to measure markers related to metabolism, inflammation, and oxidative stress. Study staff will also monitor safety and any side effects throughout the study.",[28,29,30,31,32],"Muscle","Cognitive Functioning","Geriatric","Ageing and Geriatric Health","Ageing",[34,28,35,36,37,38,39,40,41],"Health","Cognitive","Memory","natural product","ageing","natural","supplement","preservation","RECRUITING","2026-05-11",{"date":45,"type":46},"2026-05-14","ACTUAL",{"date":48,"type":46},"2026-03-06",{"date":50,"type":22},"2027-02-05",{"name":52,"class":53},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":23,"phases":65,"briefSummary":67,"conditions":68,"keywords":75,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100634736","phase-3-selenium-intervention-registry-randomized-trial-in-heart-failure-100634736","NCT07543562","Selenium Intervention Registry Randomized Trial in Heart Failure","SIRI-HF","Inclusion Criteria:\n\nTo be considered for inclusion in this study, patients must meet all of the following eligibility requirements:\n\n* 18 years of age\n* primary discharge diagnosis of HF coded as ICD-10: I50, as recorded in The SwedeHF registry\n* be able to provide documented informed consent by signing and dating the designated consent form.\n\nExclusion Criteria:\n\n* Not suitable in the opinion of the Investigator (for example due to severe or terminal comorbidity with poor prognosis, or characteristics, pregnancy etc.) that may interfere with adherence to trial protocol","18 Years",{"count":64,"type":22},4326,[66],"PHASE3","Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.\n\nSelenium is an essential micronutrient that plays an important role in cellular energy production, antioxidant defense, and overall cardiovascular function. Low selenium levels are common among patients with heart failure in Northern Europe, and observational studies have shown that selenium deficiency is associated with an increased risk of hospitalization and death. In cases of severe deficiency, such as in Keshan disease, heart dysfunction can be reversed with selenium supplementation, suggesting a potential causal relationship.\n\nHowever, it is not yet known whether selenium supplementation can improve clinical outcomes in patients with heart failure when added to standard medical therapy.\n\nThe SIRI-HF trial is a randomized, placebo-controlled study designed to evaluate whether daily supplementation with 200 micrograms of selenium, in addition to guideline-directed medical therapy, improves outcomes in patients with heart failure.\n\nThe primary endpoint is a composite of recurrent heart failure hospitalizations and cardiovascular death. Secondary endpoints include all-cause mortality, changes in symptoms and functional status, and safety outcomes.\n\nThis study will include patients from Sweden and Norway and aims to determine whether correcting selenium deficiency can improve prognosis in heart failure.",[69,70,71,72,73,74,29],"Heart Failure","Heart Failure and Reduced Ejection Fraction","Heart Failure and Mildly Reduced Ejection Fraction","Heart Failure and Preserved Ejection Fraction","Selenium Supplementation","Selenium",[76,77,78,60],"heart failure","selenium","RRCT","2026-04-15",{"date":81,"type":46},"2026-04-22",{"date":83,"type":46},"2026-04-01",{"date":85,"type":22},"2031-03",{"name":87,"class":53},"Skane University Hospital",11,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":23,"phases":100,"briefSummary":102,"conditions":103,"keywords":106,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":54},"100613512","phase-4-dual-orexin-antagonism-and-emotion-and-affective-processing-study-100613512","NCT07267559","Dual Orexin Antagonism and Emotion and Affective Processing Study","An Investigation of the Effects of Dual Orexin Antagonism on Emotional Processing and Learning in Healthy Individuals","DOREA","Inclusion Criteria:\n\n* Adult participant, aged 18 to 40 years\n* Willing and able to give informed consent for participation in the trial\n* Able to follow study procedures as laid out in the participant information sheet\n* Able to read and understand English\n* Willing to avoid drinking alcohol, using recreational drugs, drinking grapefruit juice 24 hours before and after the study visit\n* Willing to avoid driving or engaging in any activities requiring full alertness (e.g. cycling or operating heavy machinery) until the morning after the study visit day.\n* Able to complete computer tasks without eye glasses even if uses correction regularly\n\nExclusion Criteria:\n\n1. History of, receiving or seeking treatment for any sleep or circadian rhythm disorder or positive in screening questionnaires.\n2. History of, receiving or seeking treatment for any clinically significant mental health condition (including but not limited to schizophrenia, psychosis, bipolar affective disorder, major depressive disorder, obsessive compulsive disorder, post-traumatic stress disorder) or positive in screening questionnaires.\n3. History of, or current medical condition(s) which might increase the risk of oral administration of daridorexant, including:\n\n   * ADHD requiring treatment with stimulants or other centrally-acting drugs\n   * Neurological problems, including traumatic brain injury, epilepsy, Central Nervous System tumours or other severe neurological problems (e.g. Parkinson's disease; blackouts requiring hospitalisation)\n   * Current Asthma, Chronic Obstructive Pulmonary Disease, emphysema or any medical condition that affects the lungs or breathing\n   * Mild to severe hepatic impairment (Child-Pugh class A-C)\n   * Severe renal disease\n   * Severe gastrointestinal problems\n   * History of, or current medical condition(s) which, in the opinion of the Investigator may interfere with the safety of the participant or the scientific integrity of the study\n4. Pregnancy (as determined by urine pregnancy test taken during screening visit), intention to become pregnant or breastfeeding during the study or over the following six months.\n5. Body mass index (BMI) below 18 or above 30kg\u002Fm2.\n6. Current or past history of drug or alcohol dependency.\n7. Regular alcohol consumption of more than 21 units per week or use of recreational drugs or performance-enhancing drugs (e.g. cannabis, cocaine, amphetamines) within past three months.\n8. Excessive caffeine consumption, i.e., consumption higher than 400mg a day of caffeine. This corresponds to more than 4 cups of brewed coffee, 6 espressos or filtered coffees, 9 cups of black tea, 10 cans of cola, or two \"energy shot\" drinks.\n9. Smoking more than 5 cigarettes per day (or other nicotine replacement equivalent, including vaping on average more than 50 puffs a day).\n10. Current or recent (past two months) use of any medication or medical devices (e.g. implanted neurostimulator) that affect brain function for the exception of contraceptives (pill, the Depo-Provera injection or the progesterone implant). This includes drugs that cause sedation (e.g. benzodiazepines, opioids, tricyclic antidepressants or sedative antipsychotics) or antihistamines.\n11. Current use of any medications at risk of interaction with daridorexant; in particular:\n\n    * strong or moderate CYP3A inhibitors (e.g. strong inhibitors - itraconazole, clarithromycin, ritonavir, grapefruit juice; moderate inhibitors - fluconazole, verapamil, diltiazem, erythromycin, ciprofloxacin, cyclosporine)\n    * strong or moderate CYP3A inducers (e.g. of strong inducers - rifampicin, carbamazepine, St. John's wort; moderate inducers - bosentan, efavirenz, etravirine, modafinil)\n    * Gastric pH-modifiers (e.g. famotidine and proton pump inhibitors such as omeprazole)\n    * P-gp transporters (e.g. dabigatran, digoxin)\n12. Inability to ingest up to 95mg of lactose.\n13. Previous participation in any other drug study or sleep intervention study in the last three months.\n14. Previous participation in any other study by the Psychopharmacology and Emotion Research lab (Department of Psychiatry, University of Oxford) or which uses the same computer tasks in the last 6 months\n15. Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator.","40 Years",{"count":99,"type":22},62,[101],"PHASE4","In this study, the investigators will examine the effects of blocking the orexin system on human behaviour and brain function using daridorexant, a medication that inhibits orexin activity. Orexin is a brain chemical involved in regulating sleep, emotion, motivation, and stress responses, which are often disrupted in mental health disorders. Healthy volunteers will be randomly assigned to receive a single dose of daridorexant or placebo in a double-blind design. Participants will then complete behavioural and cognitive tasks assessing emotional processing, aversive learning, and executive function. The study aims to clarify the role of orexin in emotional and cognitive processes relevant to conditions such as depression and anxiety.",[104,29,105],"Learning","Emotional Processing",[107,108,109,110,104,111],"Drug","Orexin","Hypocretin","Healthy volunteers","Cognition","2026-03-16",{"date":114,"type":46},"2026-03-19",{"date":116,"type":46},"2025-10-01",{"date":118,"type":22},"2026-10-01",{"name":120,"class":53},"University of Oxford",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":17,"sex":18,"minAge":128,"maxAge":4,"enrollmentInfo":129,"targetDuration":4,"studyType":23,"phases":131,"briefSummary":132,"conditions":133,"keywords":135,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":54},"100596831","group-recreation-to-enhance-function-aging-100596831","NCT07050589","Group Recreation to Enhance Function Aging","A Community-Based Recreation Program to Improve Function and Quality of Life in Older Adults","Inclusion Criteria\n\n* \\> = 60 years of age\n* have no more than MCI (MoCA score ≥ 24 points)\n* have no contraindications to exercise, guided by the American College of Sports Medicine\n* fluent in English\n\nExclusion Criteria\n\n* have a condition that would prevent safe participation in the exercise, as determined by the Physical Activity Readiness Questionnaire for Older Adults (PAR-OA);\n* have severe neurological disease\n* have severe psychiatric illness\n* have a likelihood of withdrawing from the study due to severe illness or a life expectancy of \\\u003C 6 mo\n* have experienced a lower or upper limb amputation\n* have greater than mild cognitive impairment (MoCA score \\\u003C 24 points).","60 Years",{"count":130,"type":22},80,[25],"Investigators will develop and deliver a community-based recreation program, delivering group artmaking and group SMARTfit dual-task exergaming to community-dwelling older adults. The program will be delivered through the Buffalo-Niagara YMCA. Outcomes of interest are change in cognitive function and change in physical functioning, inresponse to 24 weeks of weekly training.",[134,29],"Physical Functioning",[136,137,138,139,140,141,142,143,144],"walking","balance","strength","attention","memory","interference inhibition","dual-task","artmaking","exergaming","2026-03-13",{"date":112,"type":46},{"date":148,"type":46},"2025-09-15",{"date":150,"type":22},"2026-07-15",{"name":152,"class":53},"State University of New York at Buffalo",{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":17,"sex":18,"minAge":62,"maxAge":19,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":54},"100575675","the-effect-of-general-anesthesia-with-remimazolam-and-propofol-on-rhythmic-state-and-cognitive-function-100575675","NCT06775366","The Effect of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function","Effects of General Anesthesia with Remimazolam and Propofol on Rhythmic State and Cognitive Function","Inclusion Criteria:\n\nAge 18-65 years old, ASAI-III class, BMI18.5-25kg\u002Fm2 Inpatients undergoing laparoscopic cholecystectomy The estimated time of operation is 1.5\\~2.5 hours Preoperative brief mental status examination (MMSE) score ≥24 Voluntary participation and signed informed consent\n\nExclusion Criteria:\n\nPregnant or lactating women Patients who are allergic to remimazolam or contraindicated Patients who are dependent on or tolerant to opioids or have long-term alcoholism Serious cardiovascular system, respiratory system, liver and kidney diseases History of obstructive sleep apnea mental disorders or neurological diseases Patients who participated in clinical trials of other drugs within the last 3 months The attending physician or researcher considers that there are other circumstances that are not suitable for participation in this study Refuse to participate in the study",{"count":161,"type":22},174,[25],"This study want to observe the effects of remimazolam and propofol for general anesthesia on postoperative rhythm and cognitive function. The observation group was given remimazolam for general anesthesia, and the control group was given propofol for general anesthesia. Both drugs are commonly used as intravenous anesthetics for general anesthesia and have been shown to be safe for use in general anesthesia. The investigators hope can understand the effects of remimazolam and propofol for general anesthesia on rhythm status and cognitive function through this study, further reduce the occurrence of postoperative cognitive function impairment, and enable subjects to better recover.",[29,165,166,167],"Propofol","Remimazolam","Circadian Rhythm","NOT_YET_RECRUITING","2025-02-12",{"date":171,"type":46},"2025-02-14",{"date":173,"type":22},"2025-02-24",{"date":175,"type":22},"2026-05-30",{"name":177,"class":53},"The Second Affiliated Hospital of Chongqing Medical University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":187,"phases":4,"briefSummary":188,"conditions":189,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":54},"100564281","expected-and-actual-preterm-birth-and-parental-distress-impact-on-childrens-mental-health-100564281","NCT06627140","Expected and Actual Preterm-Birth and Parental Distress: Impact on Children's Mental Health","Influence of Expected and Actual Preterm-Birth and Parental Distress on Children's Mental Health 6-11 Years Postpartum","Children and their parents must have participated in the previous study. Inclusion criteria of the previous study regarding the parents were:\n\n* Pregnant women and their partners from the 24th week of gestation on\n* 18 years of age\n\nExclusion criteria of the previous study were:\n\n* Psychiatric, mainly psychotic diseases\n* Drug abuse\n* Severe neurological disorders\n* Stillbirth",{"count":186,"type":22},250,"OBSERVATIONAL","The purpose of the present study is the assessment of the mental health and cognitive development of children 6-11 years after premature or term birth. Impairments in children's' mental health are assessed focusing different disorders or problems (ADHD, Autism traits, Affective disorders, oppositional-aggressive behavior) and using both questionnaires and a clinical interview. Risk and protective factors will be analyzed, e.g., threat and\u002For actual premature birth compared to term birth, parents' mental health, positive coping, personality traits and social support in the peripartum period and afterwards, as well as medical parameters. The potential interaction of premature birth, medical complications, parental distress and children's mental health will be taken into consideration.",[190,191,192,29],"Preterm Birth","Psychological Distress","Mental Health","2024-10-02",{"date":195,"type":46},"2024-10-04",{"date":197,"type":46},"2024-07-08",{"date":199,"type":22},"2024-12-20",{"name":201,"class":53},"Goethe University"]